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Objective: The objective of the study was to conduct systematic review and meta-analysis to 
establish the effect of exercise interventions on cancer-related fatigue (CRF) in cancer survivors, 
compared to non-exercise intervention controls.
Methods: Trials published between January 1st 2000 and August 17th 2016 were included 
through PubMed database search and search of references. Eligible trials compared the effect of 
an exercise intervention on CRF compared to non-exercise intervention controls, with CRF as 
primary outcome and measured by validated self-report questionnaire, in cancer survivors not 
receiving palliative care. We evaluated risk of bias of individual trials following Cochrane Quality 
criteria. We performed a random-effects meta-analysis in the low risk of bias trials with inter-
vention type, exercise intensity, adherence, and cancer type as moderators, and also performed 
meta-regression analyses and a sensitivity analysis including the high risk of bias trials.
Results: Out of 274 trials, 11 met the inclusion criteria, of which six had low risk of bias. Exercise 
improved CRF with large effect size (Cohen’s d 0.605, 95% CI 0.235–0.975) with no significant dif-
ference between types of cancer. Aerobic exercise (∆=1.009, CI 0.222–1.797) showed a significantly 
greater effect than a combination of aerobic and resistance exercises (∆=0.341, CI 0.129–0.552). 
Moderator and meta-regression analyses showed high adherence yielding best improvements.
Conclusion: Exercise has a large effect on CRF in cancer survivors. Aerobic interventions 
with high adherence have the best result.
Keywords: exercise, cancer-related fatigue, cancer survivors, randomized clinical trials, 
systematic review, meta analysis
Introduction
Background
Cancer incidence is growing, with an incidence rate of 14.1 million in 2012 and 
23.6 million new yearly cases predicted worldwide by 2030.1 Cancer incidence is high-
est in Denmark (338 cases per 100,000), followed by France (325/100,000), Australia 
(323/100,000), the USA (318 cases per 100,000), and South Korea (308/100,000) as 
top five countries. With growing incidence and current treatment possibilities, a grow-
ing number of people live beyond diagnosis. We define a person as a cancer survivor 
when he or she is living with and beyond a cancer diagnosis (like the US National 
Coalition for Cancer Survivorship).2
One of the major causes of distress in cancer survivors is cancer-related fatigue 
(CRF).3 Although in earlier research the prevalence of CRF as reported by patients in 
the USA ranged from 4% to 99%, depending on the sample and assessment method,4–6 
a recent USA-based study found a prevalence of 45% of moderate to severe CRF 
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in cancer survivors.7 Several factors have been identified in 
research as contributing to fatigue, such as treatment, emo-
tional distress, inactivity, and decondition.8 The nature of the 
fatigue is pervasive, as cancer survivors state “it’s so much 
more than just feeling tired”.9 Several trials have shown that 
exercise has a positive effect on health-related quality of life, 
physiological and psychological side effects of treatment,10 
and overall fitness,11 and may even increase survival rates.12 
It has also been suggested that there are similarities13 among 
research on chronic fatigue syndrome (CFS), which shows 
that exercise can alleviate fatigue.14,15 It is estimated that up 
to 10% of the world population suffers from chronic fatigue.10 
In all clinical settings including but not limited to oncology 
care, mental health care, general hospital care, and primary 
care, chronic fatigue prevalence rates of 40%–63% are 
reported.16 With so many people suffering from fatigue, it is 
important to be able to treat fatigue properly. A large number 
of studies have been conducted to test the effectiveness of 
treatments to reduce chronic fatigue, both in patients with 
and without chronic medical conditions, as it seems that there 
may be similarities between the chronic fatigue types.
A recent meta-analysis showed that both exercise and psy-
chological treatment have small effect sizes in CRF, whereas 
medication has no effect.11 The effect depends on cancer treat-
ment stage,11 with most effect for exercise during cancer treat-
ment, while psychotherapy has more effect after treatment.
Despite the evidence that exercise is beneficial, many 
cancer survivors do not engage in sufficient levels of exer-
cise. Survivors report a significant decline in exercise after 
diagnosis, with less than half (48%) engaging in a beneficial 
amount of exercise.17,18 Research on determinants of exer-
cise levels is limited and shows contradictory results. For 
example, one study found being female and being older to 
be associated with decreased exercise;19 another study found 
the opposite.20 Whether the nature of cancer treatment influ-
ences exercise levels of cancer survivors specifically is also 
up for debate.21 It might be that the exercise regimen is too 
strenuous; an ongoing debate concerns the question if patients 
should rest, or continue training despite malaise. It has been 
suggested in CFS patients that exercise improves fatigue 
but too much exercise has adverse effects, resulting in low 
adherence;22 post-exercise malaise is a frequent reason to stop 
an exercise regimen.23 Being fatigued is a valid reason for a 
person without cancer not to exercise, and the larger burden 
of CRF might make it even harder to exercise.
Rationale
CRF, because of its persistence and interference with many 
aspects of daily life,24 even in cancer survivors with no 
evidence of active disease,25,26 leads to loss of work, limited 
social functioning including parenting, and even lower 
treatment adherence. In view of its high prevalence of 45%, 
combined with growing survival rates, CRF can be consid-
ered as a major public health concern. An often dispensed 
advice is to exercise, but it is not clear how and with which 
intensity. Research is warranted that aims to clarify this.
A Cochrane systematic review and meta analysis by 
Cramp and Byron-Daniel27 examined the effect of exercise 
on CRF in cancer survivors. Patients received non-palliative 
treatment or palliative treatment. Also, this review included 
CRF as secondary outcome. As we intend to establish the 
effect of exercise on CRF as a primary outcome in a popula-
tion not suffering from specific end-of-life distress, we have 
only included trials evaluating exercise interventions versus 
non-exercise intervention controls, with CRF as a primary 
outcome measure. Hence, the results of this meta-analysis may 
provide the clinician with clear-cut information if exercise 
should be recommended, and what kind of exercise to recom-
mend to cancer survivors not receiving palliative care.
Objectives
This study aims to provide a systematic review of RCTs 
evaluating the effect on CRF of exercise interventions versus 
non-exercise intervention controls in cancer survivors not 
receiving palliative care in trials evaluating CRF as a pri-
mary outcome measure. In our review, both level of exercise 
intensity and adherence are taken into account. The ensuing 
meta-analysis will provide a pooled estimate of the effect.
Methods
Protocol and registration
The review protocol has been registered in the Prospero Centre 
for reviews and dissemination28 under ID CRD42013003670. 
The systematic review and meta-analysis are performed 
and presented according to PRISMA Guidelines and with a 
PRISMA checklist (Figure S1).29
eligibility criteria
An overview of participants, interventions, comparisons, 
outcomes, and study design (PICOS) is shown in Table 1. 
Patients were adults (18 years or older), regardless of sex, 
living with and beyond any cancer diagnosis. Patients were 
not receiving palliative care in the sense of symptom reduc-
tion in advanced disease, but may receive active treatment 
such as surgery, chemotherapy, or radiation therapy. Patients 
with metastatic disease were not included. Any length of 
follow-up was acceptable for inclusion and included in the 
data synthesis; however, for comparability of estimate of the 
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effect, in the meta-analysis similar length of follow-up was 
chosen between studies.
information sources
A PubMed database and a Cochrane Database search were 
performed. We also hand-searched the references noted by 
Cramp and Byron-Daniel27 in their Cochrane review and each 
included article. Furthermore, we contacted study authors to 
identify relevant data for the analysis.
Search
The MeSH terms and free text terms used were “cancer” 
AND “fatigue” AND (“physical activity” OR “exercise”) 
AND “randomized controlled trial”. The search string 
was “cancer”[All Fields] AND “fatigue”[All Fields] 
AND (“physical activity”[All Fields] OR “exercise”[All 
Fields]) AND “randomized controlled trial”[All Fields]. 
For the Cochrane Database, the search was adapted to sys-
tematic reviews.
The search was limited to articles published between 
January 1st 2000 and August 17th 2016. There were no 
language or other search limitations.
Study selection
We included RCTs that evaluated any exercise interven-
tion in any setting, individually or in a group, to study the 
effect on CRF in cancer survivors. The intervention was of 
sufficient intensity as measured in metabolic equivalent of 
the task (MET), thus not including stretching exercises. We 
also excluded yoga; although the majority of yoga sessions 
are of very light intensity,30 quite strenuous yoga exercise 
also exists and specific characteristics of the yoga interven-
tion are usually not given. Comparisons were with a control 
group, not receiving any (major) exercise intervention or 
other intervention (eg, cognitive behavioral therapy). Primary 
outcome had to be CRF and was expressed in quantitative 
measures by a validated self-report questionnaire.
Titles and subsequent abstracts of trials were retrieved 
and screened in duplicate by two independent reviewers 
(EK and OH) to identify trials that met the inclusion criteria. 
In case of disagreement, an independent third reviewer (CFC) 
gave her opinion regarding eligibility and the article was 
selected based on combination of the three. Subsequently, 
the full text of potentially eligible trials was retrieved and 
independently assessed for eligibility in duplicate by two 
independent reviewers (EK, OH) and the third reviewer in 
case of disagreement. Thereafter, risk of bias was assessed. 
For the meta-analysis, only RCTs with low risk of bias 
assessment were included. A flow chart will be presented in 
the subsection “Study selection”.
Data collection process
Data was extracted by two authors (EK, OH). When insuf-
ficient data were available in the full text, authors were 
contacted by email for further information.
Data items
The main variable for which data was sought is:
1) CRF severity, measured by self-report questionnaire 
validated to assess fatigue in cancer patients.
Table 1 PiCOS eligibility criteria
Parameter Inclusion criteria Exclusion criteria
Patients Adults .18 years living with, through, or 
beyond a cancer diagnosis not receiving 
palliative care
Patients under 18 years of age
Patients receiving palliative care
Patients with metastatic cancer
intervention Physical activity intervention of sufficient 
intensity as measured by MeTs
An information letter/session
education
Yoga (of insufficient METs)
Stretching
Comparator Non-exercise control group Non-exercise control group receiving 
additional care, such as CBT
Outcomes Primary outcome: intensity of CRF as measured 
by self-report questionnaire
Secondary outcome: adherence
CRF is not the primary outcome
Study design Randomized controlled trials published between 
January 1st 2000 and August 17th 2016
No language restrictions
Non-randomized controlled trials
Retrospective, prospective, or 
concurrent cohort studies
Cross-sectional studies
Case reports
editorials and opinion pieces
Abbreviations: CBT, cognitive behavioral therapy; CRF, cancer-related fatigue; MeTs, metabolic equivalents of task; PiCOS, patients, intervention, comparator, outcomes, 
study design.
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Other moderating variables for which data were sought 
are:
1) Number of patients in intervention and control groups.
2) Type of exercise intervention.
3) Type of cancer.
4) Current stage of treatment and type of treatment 
received.
5) Intensity of exercise intervention in METs/hour; if MET 
was not mentioned, it was calculated (OH) based on the 
described characteristics of the intervention.31
6) Adherence percentages; we made an assessment based 
on three aspects: level of reporting, adherence rates as a 
percentage based on the information in the trials regarding 
adherence, in terms of sessions attended, and if reporting 
was done by supervisor or self-report. Adherence level 
then was determined on a combined assessment of these 
three aspects, and split into three groups: low (,60%), 
moderate (60%–80%), and high (.80%). This is 
indicated in a data extraction table (Table 2).
Risk of bias in individual trials
Two independent assessors (EK, OH) assessed the risk of bias 
of included trials on study level (not on outcome level) on the 
basis of the Cochrane Quality criteria, of which randomiza-
tion is considered the most important.32 Any disagreement 
on eligibility was resolved through discussion with the third 
reviewer (CFC). Results are shown in a risk-of-bias table 
(Table 3). Trials with low risk of bias, adequately address-
ing more than half ($4/7) of the items, were included in the 
meta-analysis.
Summary measures
The principal summary measure was expressed as standard-
ized difference in means (Cohen d) of CRF. These effect 
sizes indicate by how many standard units the intervention 
group is better off than the control group. The effect size d 
is calculated by subtracting the average score of the control 
group (M
c
) from the average score of the experimental group 
(M
e
) and dividing the raw difference score by the pooled 
standard deviation of the experimental and control group. 
An effect size of 0.5 indicates that the mean of the experi-
mental group is half a standard unit larger than the mean of 
the control group. It is generally assumed that an effect size 
of 0.56–1.2 represents a large clinical effect, 0.33–0.55 is 
medium, and below 0.33 is small.33 If trials reported more 
than one (validated) self-report measure for fatigue, we used 
only one in the analysis that was preferably also used in other 
trials. For the benefit of clinical relevance, we chose to use 
the outcomes at post-intervention, not at longer follow-up, 
in the meta-analysis.
Synthesis of results
We have provided a synthesis of results (Table 2) with an 
overview of type of cancer, intervention, and outcome. 
Subsequently, a random-effects meta-analysis was per-
formed. Between-study heterogeneity was assessed by the 
observed dispersion, reflected by the Q-statistic. The I2 sta-
tistic shows the percentage of total variation across trials that 
is the result of heterogeneity rather than chance and was used 
to quantify this dispersion.34 The statistical program Compre-
hensive Meta-Analysis v.235 was used for all analyses.
Risk of bias across trials
A test of publication bias was performed in order to assess 
evidence for publication bias and if the reported effect was 
valid. Publication bias was examined by constructing a Begg 
funnel plot36 and performing as the fail-safe N.37
Additional pre-envisioned moderator 
analyses
We planned several moderator analyses, which are as 
follows:
Type of intervention
Type of intervention was split into three groups: aerobic, 
resistance, and a combination of resistance and aerobic 
exercise. Aerobic exercise is physical exercise that depends 
primarily on the aerobic energy-generating process.38 This 
refers to the use of oxygen to adequately meet energy 
demands during exercise via aerobic metabolism.39 Examples 
are walking, running, swimming, and cycling.
Resistance exercise is physical exercise that induces 
muscular contraction that builds the strength, endurance, and 
size of skeletal muscles as anaerobic activity associated with 
lactate production. Training commonly uses the technique 
of progressively increasing the force output of the muscle by 
increasing weight and using a variety of exercises to target spe-
cific muscle groups.40 Examples are weightlifting and rowing.
Type of cancer
Type of cancer was split into four groups: breast cancer, 
prostate cancer, gynecological cancer, and mixed.
intensity of exercise
Intensity of exercise was split into high or low intensity (in 
METs/hour):32 high MET was operationalized as at least 
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3.5 METs per day at least 5 days a week, adding up to $17.5. 
Low MET was ,17.5. For linear meta-regression, the actual 
MET scores were used.
Adherence
Adherence was split into three groups: low (,60%), moderate 
(60%–80%), and high (.80%). For linear meta-regression, 
adherence percentages as reported in the trials were used.
After performing each analysis we examined hetero-
geneity. We performed a sensitivity analysis also including 
the articles with high risk of bias.
Results
Study selection
The search strategy yielded 274 hits, 246 after checking 
for duplicates. Searching the Cochrane Database provided 
one systematic review,28 of which we hand-searched the 
references. After independently screening title and abstracts, 
35 trials were included for independent full-text screening. 
We were not able to procure a translated version in English 
or Dutch for one study published in Korean. Twenty-four 
trials were excluded and finally 11 trials met the inclusion 
criteria as stated in the subsection “Study selection” and 
were included in the systematic review. Five of these were 
excluded because of high risk of bias and six were included 
in the meta-analysis. However, all 11 trials were included 
in the sensitivity analysis. See the PRISMA Flow Diagram 
(Figure 1) for an overview and exclusion reasons.
Study characteristics
All 11 trials were RCTs.41–52 In total, 788 patients were 
included in the trials, 411 of which received an exercise 
intervention and 377 were randomized in a non-exercise 
intervention control group as described in the section 
“Eligibility criteria”. In five trials,42,44,46,47,49 patients were 
still undergoing cancer treatment during the intervention, in 
one study there was no active cancer treatment,43 and in the 
other five trials45,48,50–52 some patients were still undergoing 
cancer treatment but outcome reporting of fatigue scores was 
not differentiated between patients still undergoing cancer 
treatment or not. Post-intervention follow-up assessments of 
CRF varied from 4 weeks34 to 12–24 weeks.50,51
Risk of bias
Risk of bias was determined for 11 trials on study level and 
is presented in Table 3. Several trials did not adequately 
address allocation concealment, missing data, and blinding. 
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effect of exercise on CRF in cancer survivors: systematic review and meta-analysis
Trials not scoring the maximum may be underestimated 
due to lack of reporting. Six trials42,43,45,47,48,51 fulfilled the 
majority of criteria to eliminate risk of bias and were thus 
considered of sound quality. Five trials were assessed as 
being high risk of bias and were excluded from the initial 
meta-analysis.44,46,49,50,52 The risk of bias assessment showed 
that these trials failed to provide important information, such 
as not adequately describing the randomization procedure,49 
testing one-sided while the research question was clearly 
two-sided,52 or otherwise as indicated.
Results of individual trials
The meta-analysis was performed first with the six low risk 
of bias trials. Later, a sensitivity analysis was performed with 
all 11 RCTs. The results are summarized in Table 2.
intervention characteristics and 
supervision
Eight trials found significant improvements in CRF,42,43,45,47–49,51 
and one found a significant effect for exercise after correct-
ing for adherence to the intervention.46 Two found no effect 
on CRF.44,50 Three types of exercise interventions were 
distinguished: aerobic exercise;43,44,46,49–51,52 resistance exercise, 
which was not evaluated as stand-alone exercise intervention 
in the selected trials; and a mix of both.42,45,47,48 Three trials 
offered a fully supervised exercise program at a health care 
location,42,43,48 eight offered home-based interventions with 
monitoring methods like a wristband monitor,50 follow-up 
calls,44,45 or logs.46,47,49,51,52 Intensity of the exercise interven-
tions in METs varied: the exercise programs combining aero-
bics and resistance exercises42,47,48 and one aerobic program44 
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Figure 1 PRISMA 2009 flow diagram.
Abbreviation: CRF, cancer-related fatigue.
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were of high intensity, and the other aerobic exercise pro-
grams were of low intensity.43,46,49–52 One study did not pro-
vide enough information to determine METs:45 their patients 
did not keep detailed records of their home exercise.
Outcome measure characteristics
The timing of measurements varied and for the benefit of 
clinical relevance, and to enable us to pool similar results, 
we chose to use the outcomes at post-intervention, not the 
outcomes at follow-up, as this differed greatly between trials 
and long-term follow-up might depend on other factors than 
the intervention alone.
Synthesis of results (meta-analysis)
In order to establish the overall effect of exercise on CRF, a 
first meta-analysis was performed for CRF outcomes of the 
six low risk of bias trials. See Figure 2 for the forest plot. 
The effects were presented in terms of standardized effect 
sizes (Cohen’s d). The results of the random analysis showed 
that any exercise improves CRF, compared to controls. The 
pooled estimate of the effect size was large (0.605, 95% CI 
0.235–0.975). Heterogeneity (Q-value) of this effect was 
Q (2) =15, p=0.010. The I2 statistic was 67%, indicating suf-
ficient heterogeneity to use a random model to fit the data.
Pre-envisioned moderator analyses
Several pre-envisioned moderator analyses were performed: 
cancer type, intervention type, MET, and adherence.
Cancer type
Two trials included patients with breast cancer,43,48 one 
included prostate cancer,47 one included gynecological 
cancers,45 and the other two trials were categorized as “mixed 
cancer”.42,51 The moderator analysis of type of cancer showed 
no significant heterogeneity between these four cancer types 
(Q (3) =3.7, p=0.295 (ns)).
Type of exercise intervention
A moderator analysis of intervention type was performed. 
The two aerobic exercise trials43,51 (∆=1.009, CI 0.222–
1.797) show a significantly greater effect than the four 
trials42,45,47,48 examining a combination of aerobic and 
resistance exercises (∆=0.341, CI 0.129–0.552). There was 
no significant heterogeneity between groups (Q (1) =2.6, 
p=0.108 (ns)).
MeT
Using MET as a moderator to explore the role of intensity of 
exercise, one study45 could not be taken into account as we 
had insufficient data to calculate MET intensity. We performed 
a meta-regression analysis that showed better results for low 
MET intensity; however, this finding was not significant.
Adherence
The meta-regression analysis showed a significant effect of 
adherence on effect size (Q (1) =5.925, p=0.01). With low 
adherence (,56%), the effect size is 0. With high adherence, 
the effect size becomes large, going up to 0.8 for 100% 
adherence (see Figure 3).
Sensitivity analysis
We performed an additional sensitivity analysis, including 
the five trials with high risk of bias. This did not change the 
outcome that exercise improves CRF compared to controls. 
The pooled effect size was diminished slightly, but still 
medium (0.465, 95% CI 0.217, 0.712). Heterogeneity of this 
effect was Q (10) =26, p#0.01. The I2 statistic was 63%.
Publication bias
A test for publication bias was performed. The fail-safe 
N showed that 42 additional trials should be added to the 
analysis before the cumulative effect would become statisti-
cally non-significant. Given the fact that only 11 trials could 
be identified that specifically looked at the effect of exercise 
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Figure 2 Forest plot of effect on CRF.
Abbreviation: CRF, cancer-related fatigue; eORTC QLQ-C30, european Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; PFS, 
Piper Fatigue Scale; MFSi-SF, Multidimensional Fatigue Symptom inventory-Short Form; PROMiS, Patient-Reported Outcomes Measurement information System; Std diff, 
standard difference.
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on CRF as a primary outcome compared to a non-exercise 
control group, and only six of those addressed risk of bias 
sufficiently, it is unlikely that 42 trials were missed. This 
indicates that no significant publication bias seems to be the 
case and the reported effect is valid.
Discussion
Summary of evidence
This study provides us with the possibility to estimate 
the effect of exercise, the surplus value of aerobic exer-
cise, and the importance of adherence in cancer survivors 
who may or may not still be under treatment, but not in a 
terminal phase.
We found a clear improvement in CRF as a result of 
exercise interventions, with a large effect size. Aerobic 
exercises showed better improvement than a combination of 
aerobic and resistance exercises. Adherence to the interven-
tion is important: high adherence resulted in a large effect, 
whereas low or moderate adherence yielded small effects. 
These effects were the same for all cancer types in the study. 
The indication that low-intensity exercise might be more 
effective than high-intensity exercise was not significant in 
a meta-regression.
Comparison with other studies
This finding is in sync with the National Comprehensive 
Cancer Network guidelines on treating CRF,8 which note that 
exercise is one of the most effective non-pharmacological 
treatments for CRF. Embedding of exercise programs in 
current oncologic rehabilitation guidelines is, however, still 
not standard. Our results clearly indicate that this should be 
considered.
Other studies report that CRF is highly associated with 
pain, insomnia, and psychological distress factors like 
depression;52 similar findings have been reported in CFS.53 
These symptoms may arise through a common pathway, 
as previous research on inflammation and CRF suggests 
that tumours and the treatments used to treat them activate 
proinflammatory cytokines, leading to CRF and other 
symptoms.54 Similar suggestions have been made for CFS,55 
as difficulty in following through with exercise has also been 
found in chronic fatigue patients. It has been suggested that 
exercise does improve fatigue; however, too much exercise 
might have adverse effects resulting in low adherence to the 
exercise protocol.56 It might be somewhat surprising that 
low-intensity exercise is more effective than high-intensity 
exercise. However, this finding is in sync with findings in 
CFS that overriding leads to more post-exercise malaise 
than pacing yourself and grading activities.57 This may be 
an indication that for handling fatigue, low exercise may 
be enough and that strenuous exercise is not needed to get 
good results. This finding warrants further research in treat-
ment modes for fatigue in general.
Another important factor to address is adherence. 
Pathophysiological or mental barriers, or fatigue by itself 
could hinder patients from becoming (more) active.58 Our 
results show high adherence rates leading to better CRF 
outcomes. Information provision by health care professionals 
might ensure adherence; other methods are sufficient profes-
sional support, tailored advice, clear individual goals, and 
including the support system.59,60
implications
The finding that exercise leads to lower levels of CRF 
underlines the importance of focussing upon physical train-
ing in the care of cancer patients. Exercise programs can 
have a direct effect on CRF by increasing muscle strength 
and physical fitness to counteract physical deconditioning. 
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Figure 3 Meta-regression plot of adherence.
Abbreviation: Std diff in means, standard difference in means.
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However, exercise can also have an indirect effect on CRF. 
CRF is highly associated with physical distress factors like 
pain and insomnia and psychological distress factors like 
depression and anxiety on CRF. Similar findings have been 
reported in CFS.54 It may be that these symptoms arise 
through a common pathway as previous research on inflam-
mation and CRF suggests that tumours and the treatments 
used to treat them activate proinflammatory cytokines, 
leading to CRF and other symptoms.55 Similar sugges-
tions have been made for CFS, which has as characteristic 
that, apart from the fatigue, other symptoms should be 
present, such as memory or concentration problems, muscle 
pain, joint pain, headache, sleeping problems, and malaise 
after exercise.56,61 Exercise can reduce CRF indirectly by its 
beneficial effects on mood, immune functioning, or sleep.62 
In that sense, working mechanisms of exercise might have 
aspects similar to those in CFS. This should be a topic of 
further research.
The findings in this review may therefore be relevant 
not only for cancer survivors, but also, more in general, 
for people suffering from chronic fatigue, as it provides 
clinicians with concrete tools to enhance the possibility for 
adherence to exercise protocols. This should be a topic for 
future research.
Limitations
The main limitation of this study is that the number of trials 
was small and that only six were of low risk of bias. The 
randomization procedures are not addressed sufficiently to 
evaluate or reproduce, and allocation concealment/blinding 
was sometimes not mentioned at all. Moreover, in many trials, 
active treatment status was not addressed properly. Trials 
included in the review have different timeframes: some were 
during active treatment and others were after primary treat-
ment or a combination of the two. There is a need for RCTs 
of better quality in this field. However, a sensitivity analysis 
including the high risk of bias trials showed that the effect of 
exercise versus non-exercise still remained positive.
Furthermore, most patients in our sample were “early” 
cancer survivors as many were still undergoing treatment dur-
ing the RCT. It is unclear if our recommendations for exercise 
are valid for long-term cancer survivors. Research with long-
term survivors and longer follow-up is clearly needed.
Furthermore, trials with widely divergent cancer types are 
included. Although this enables us to estimate the effect as 
a general intervention in all types of cancer, more trials for 
specific cancer types would be needed to estimate the effect 
in specific cancer types and their specific treatments.
Strengths
Comparison with a previous meta-analysis shows several 
methodological differences. We only included RCTs with 
non-exercise intervention controls; the ones that studied 
CRF as a primary outcome and patients receiving palliative 
care were not included. In contrast to the study of Cramp 
and Byron-Daniel,27 we were able to conduct sub-analyses 
for type and intensity of exercise, which enabled us to find 
clear cues for exercise regimens.
Conclusion
Based on this review, we conclude that exercise effectively 
improves CRF, especially with high adherence rates. The 
clinical recommendation is to improve exercise in cancer 
survivors with an exercise intervention that includes aerobic 
exercise and with high focus on facilitating adherence. 
Research implications are that more research of sufficient 
quality is needed. Future research should preferably assess 
CRF as a primary outcome.
Acknowledgment
Mw drs L Ossewaarde was involved in an early stage in setting 
up the database search. No other contributions were made.
Disclosure
A poster with preliminary results without pooled estimate 
was previously presented at the Dutch psychiatry association 
(NVvP) congress on April 10th 2014. The authors report no 
conflicts of interest in this work.
References
1. Cancer Research UK. Worldwide cancer incidence statistics. 2014. Avail-
able from: http://www.cancerresearchuk.org/cancer-info/cancerstats/
world/incidence. Accessed November 13, 2017.
2. US National Coalition for Cancer Survivorship. Defining cancer survi-
vorship. Available from: http://www.canceradvocacy.org/news/defining-
cancer-survivorship. Accessed November 13, 2017.
3. Akechi T, Kugaya A, Okamura H, Yamawaki S, Uchitomi Y. Fatigue 
and its associated factors in ambulatory cancer patients: a preliminary 
study. J Pain Symptom Manage. 1999;17(1):42–48.
4. Hofman M, Morrow GR, Roscoe JA, et al. Cancer patients’ expectations 
of experiencing treatment-related side effects: a University of Rochester 
Cancer Center–Community Clinical Oncology Program study of 938 
patients from community practices. Cancer. 2004;101(4):851–857.
5. Patrick DL, Ferketich SL, Frame PS, et al; National Institutes of Health 
State-of-the-Science Panel. National Institutes of Health State-of-the-
Science Conference Statement: symptom management in cancer: pain, 
depression, and fatigue, July 15–17, 2002. J Natl Cancer Inst Monogr. 
2004;(32):9–16.
6. Cella D, Davis K, Breitbart W, Curt G; Fatigue Coalition. Cancer-related 
fatigue: prevalence of proposed diagnostic criteria in a United States 
sample of cancer survivors. J Clin Oncol. 2001;19(14):3385–3391.
7. Wang XS, Zhao F, Fisch MJ, et al. Prevalence and characteristics of 
moderate to severe fatigue: a multicenter study in cancer patients and 
survivors. Cancer. 2014;120(3):425–432.
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
62
.2
18
.7
9 
on
 2
7-
Fe
b-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2018:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
491
effect of exercise on CRF in cancer survivors: systematic review and meta-analysis
 8. NCCN Clinical Practice Guidelines in Oncology. Cancer-related fatigue. 
Version 2. 2017. Available from: https://www.nccn.org/professionals/
physician_gls/pdf/fatigue.pdf. Accessed November 13, 2017.
 9. Wu HS, McSweeney M. Cancer-related fatigue: “It’s so much more 
than just being tired”. Eur J Oncol Nurs. 2007;11(2):117–125.
 10. Son CG. Review of the prevalence of chronic fatigue worldwide. 
J Korean Orient Med. 2012;33(2):25–33.
 11. Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceuti-
cal, psychological, and exercise treatments for cancer-related fatigue: 
a meta-analysis. JAMA Oncol. 2017;3(7):961–968.
 12. Hall AE, Boyes AW, Bowman J, Walsh RA, James EL, Girgis A. Young 
adult cancer survivors’ psychosocial well-being: a cross-sectional study 
assessing quality of life, unmet needs, and health behaviors. Support 
Care Cancer. 2012;20(6):1333–1341.
 13. Wessely S, Powell R. Fatigue syndromes: a comparison of chronic 
“postviral” fatigue with neuromuscular and affective disorders. J Neurol 
Neurosurg Psychiatry. 1989;52(8):940–948.
 14. Sharpe M, Goldsmith KA, Johnson AL, Chalder T, Walker J, White PD. 
Rehabilitative treatments for chronic fatigue syndrome: long-term follow- 
up from the PACE trial. Lancet Psychiatry. 2015;2(12):1067–1074.
 15. Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy 
for chronic fatigue syndrome. Cochrane Database Syst Rev. 2015;(2): 
CD003200.
 16. Kellner R, Sheffield BF. The one-week prevalence of symptoms in 
neurotic patients and normals. Am J Psychiatry. 1973;50:734–741.
 17. Humpel N, Iverson DC. Depression and quality of life in cancer 
survivors: is there a relationship with physical activity? Int J Behav 
Nutr Phys Act. 2007;4:65.
 18. Midtgaard J, Baadsgaard MT, Møller T, et al. Self-reported physical 
activity behaviour; exercise motivation and information among Danish 
adult cancer patients undergoing chemotherapy. Eur J Oncol Nurs. 2009; 
13(2):116–121.
 19. Drewnowski A, Evans WJ. Nutrition, physical activity, and quality of 
life in older adults: summary. J Gerontol A Biol Sci Med Sci. 2001; 
56 Spec No 2:89–94.
 20. Jones LW, Courneya KS, Vallance JK, et al. Understanding the determinants 
of exercise intentions in multiple myeloma cancer survivors: an application 
of the theory of planned behavior. Cancer Nurs. 2006;29(3):167–175.
 21. Servaes P, van der Werf S, Prins J, Verhagen S, Bleijenberg G. Fatigue 
in disease-free cancer patients compared with fatigue in patients with 
chronic fatigue syndrome. Support Care Cancer. 2001;9(1):11–17.
 22. Williams TE, Chalder T, Sharpe M, White PD. Heterogeneity in chronic 
fatigue syndrome – empirically defined subgroups from the PACE trial. 
Psychol Med. 2017;47(8):1454–1465.
 23. Van Houdenhove B, Luyten P. Chronic fatigue syndrome reflects loss 
of adaptability. J Intern Med. 2010;268(3):249–251.
 24. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of 
fatigue severity in cancer patients: use of the Brief Fatigue Inventory. 
Cancer. 1999;85(5):1186–1196.
 25. Servaes P, Gielissen MF, Verhagen S, Bleijenberg G. The course of 
severe fatigue in disease-free breast cancer patients: a longitudinal 
study. Psychooncology. 2007;16(9):787–795.
 26. Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome 
symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. 
J Clin Oncol. 2012;30(30):3687–3696.
 27. Cramp F, Byron-Daniel J. Exercise for the management of cancer-
related fatigue in adults. Cochrane Database Syst Rev. 2012;11: 
CD006145.
 28. Kessels E, Husson O, van der Feltz-Cornelis CM. Review protocol. 
2017. Available from: http://www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42013003670. Accessed January 10, 
2018.
 29. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred 
reporting items for systematic reviews and meta-analyses: the PRISMA 
statement. J Clin Epidemiol. 2009;62(10):1006–1012.
 30. Larson-Meyer DE. A systematic review of the energy cost and metabolic 
intensity of yoga. Med Sci Sports Exerc. 2016;48(8):1558–1569.
 31. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical 
activities: an update of activity codes and MET intensities. Med Sci 
Sports Exerc. 2000;32(9 Suppl):S498–S504.
 32. Higgins JP, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods 
Group; Cochrane Statistical Methods Group. The Cochrane Col-
laboration’s tool for assessing risk of bias in randomised trials. BMJ. 
2011;343:d5928.
 33. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. 
Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
 34. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring incon-
sistency in meta-analyses. BMJ. 2003;327(7414):557–560.
 35. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Comprehensive 
Meta-analysis. (Version 2.2.027) [Computer software]. Englewood, NJ: 
Biostat; 2005.
 36. Begg CB. Publication bias. In: Cooper H, Hedges LV, editors. The 
Handbook of Research Synthesis. New York: Russell Sage Foundation; 
1994:399–409.
 37. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to 
Meta-analysis (Statistics in Practice). Chichester, UK: John Wiley & 
Sons; 2009.
 38. Sharon A Plowman, Denise L Smith. Exercise Physiology for Health, 
Fitness, and Performance. Philadelphia, Lippincott Williams & 
Wilkins; 2001:61.
 39. William D McArdle, Frank I Katch, Victor L Katch. Essentials of 
Exercise Physiology. Philadelphia, Lippincott Williams & Wilkins; 
2006:204.
 40. Peterson MD, Gordon PM. “Resistance exercise for the aging adult: 
clinical implications and prescription guidelines”. Am J Med. 2011; 
124(3):194–198.
 41. Adamsen L, Quist M, Andersen C, et al. Effect of a multimodal 
high intensity exercise intervention in cancer patients undergo-
ing chemotherapy: randomised controlled trial. BMJ. 2009;339: 
b3410.
 42. Cantarero-Villanueva I, Fernández-Lao C, Cuesta-Vargas AI, Del 
Moral-Avila R, Fernández-de-Las-Peñas C, Arroyo-Morales M. The 
effectiveness of a deep water aquatic exercise program in cancer-related 
fatigue in breast cancer survivors: a randomized controlled trial. Arch 
Phys Med Rehabil. 2013;94(2):221–230.
 43. Dodd MJ, Cho MH, Miaskowski C, et al. A randomized controlled trial 
of home-based exercise for cancer-related fatigue in women during and 
after chemotherapy with or without radiation therapy. Cancer Nurs. 
2010;33(4):245–257.
 44. Donnelly CM, Blaney JM, Lowe-Strong A, et al. A randomised con-
trolled trial testing the feasibility and efficacy of a physical activity 
behavioural change intervention in managing fatigue with gynaecologi-
cal cancer survivors. Gynecol Oncol. 2011;122(3):618–624.
 45. Mock V, Frangakis C, Davidson NE, et al. Exercise manages fatigue 
during breast cancer treatment: a randomized controlled trial. 
Psychooncology. 2005;14(6):464–477.
 46. Mustian KM, Peppone L, Darling TV, Palesh O, Heckler CE, 
Morrow GR. A 4-week home-based aerobic and resistance exercise 
program during radiation therapy: a pilot randomized clinical trial. 
J Support Oncol. 2009;7(5):158–167.
 47. Rogers LQ, Vicari S, Trammell R, et al. Biobehavioral factors mediate 
exercise effects on fatigue in breast cancer survivors. Med Sci Sports 
Exerc. 2014;46(6):1077–1088.
 48. Wang YJ, Boehmke M, Wu YW, Dickerson SS, Fisher N. Effects of a 
6-week walking program on Taiwanese women newly diagnosed with 
early-stage breast cancer. Cancer Nurs. 2011;34(2):E1–E13.
 49. Windsor PM, Nicol KF, Potter J. A randomized, controlled trial of 
aerobic exercise for treatment-related fatigue in men receiving radical 
external beam radiotherapy for localized prostate carcinoma. Cancer. 
2004;101(3):550–557.
 50. Yeo TP, Burrell SA, Sauter PK, et al. A progressive postresection walk-
ing program significantly improves fatigue and health-related quality 
of life in pancreas and periampullary cancer patients. J Am Coll Surg. 
2012;214(4):463–475. discussion 475–477.
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
62
.2
18
.7
9 
on
 2
7-
Fe
b-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2018:14submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
492
Kessels et al
 51. Yuen HK, Sword D. Home-based exercise to alleviate fatigue and 
improve functional capacity among breast cancer survivors. J Allied 
Health. 2007;36(4):e257–e275.
 52. Seo Y, Oh H, Seo W. Causal relationships among factors associated 
with cancer-related fatigue. Eur J Oncol Nurs. 2010;14(5):380–386.
 53. Kempke S, Goossens L, Luyten P, Bekaert P, Van Houdenhove B, 
Van Wambeke P. Predictors of outcome in a multi-component treatment 
program for chronic fatigue syndrome. J Affect Disord. 2010;126(1–2): 
174–179.
 54. Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: 
mechanisms, contributing factors, and treatment implications. Brain 
Behav Immun. 2013;30 Suppl:S48–S57.
 55. Van Houdenhove B, Van Den Eede F, Luyten P. Does hypothalamic-
pituitary-adrenal axis hypofunction in chronic fatigue syndrome reflect 
a ‘crash’ in the stress system? Med Hypotheses. 2009;72(6):701–705.
 56. Williams TE, Chalder T, Sharpe M, White PD. Heterogeneity in chronic 
fatigue syndrome – empirically defined subgroups from the PACE trial. 
Psychol Med. 2017:1–12.
 57. Van Houdenhove B, Bruyninckx K, Luyten P. In search of new balance. 
Can high “action-proneness” in patients with chronic fatigue syndrome 
be changed by a multidisciplinary group treatment? J Psychosom Res. 
2006;60(6):623–625.
 58. Courneya KS, Friedenreich CM, Quinney HA, et al. A longitudinal 
study of exercise barriers in colorectal cancer survivors participat-
ing in a randomized controlled trial. Ann Behav Med. 2005;29(2): 
147–153.
 59. Husebø AM, Karlsen B, Allan H, Søreide JA, Bru E. Factors perceived 
to influence exercise adherence in women with breast cancer participat-
ing in an exercise programme during adjuvant chemotherapy: a focus 
group study. J Clin Nurs. 2015;24(3–4):500–510.
 60. Piotrowicz E, Orzechowski P, Chrapowicka A, Piotrowicz R. How 
should we advise heart failure patients on exercise and what should 
we tell them? Curr Heart Fail Rep. 2014;11(3):274–280.
 61. van Houdenhove B, Heijnen CJ. [Chronic fatigue syndrome: a psy-
choneuroimmunological perspective]. Tijdschr Psychiatr. 2009;51(8): 
603–610. Dutch.
 62. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komarfoff A. 
The chronic fatigue syndrome: a comprehensive approach to its defini-
tion and study. International Chronic Fatigue Syndrome Study Group. 
Ann Intern Med. 1994;121(12):953–959.
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
62
.2
18
.7
9 
on
 2
7-
Fe
b-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2018:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
493
effect of exercise on CRF in cancer survivors: systematic review and meta-analysis
Supplementary material
Section/topic # Checklist item Reported 
on page 
#
TITLE
Title 1 identify the report as a systematic review, meta-analysis, or both. 1
ABSTRACT
Structured  
summary
2 Provide a structured summary including, as applicable, background; objectives; data sources; study  
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results;  
limitations; conclusion and implications of key findings; systematic review registration number.
3
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is already known. 5
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions,  
comparisons, outcomes, and study design (PICOS).
6
METHODS
Protocol and  
registration
5 Indicate if a review protocol exists, if and where it can be accessed (eg, web address), and, if available,  
provide registration information including registration number.
6
eligibility  
criteria
6 Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years  
considered, language, publication status) used as criteria for eligibility, giving rationale.
6
information  
sources
7 Describe all information sources (eg, databases with dates of coverage, contact with study authors to  
identify additional studies) in the search and date last searched.
7
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it  
could be repeated.
7
Study selection 9 State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if  
applicable, included in the meta-analysis).
7
Data collection  
process
10 Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and any  
processes for obtaining and confirming data from investigators.
8
Data items 11 List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions  
and simplifications made.
8
Risk of bias in  
individual trials
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether  
this was done at the study or outcome level), and how this information is to be used in any data synthesis.
8
Summary  
measures
13 State the principal summary measures (eg, risk ratio, difference in means). 9
Synthesis of  
results
14 Describe the methods of handling data and combining results of studies, if done, including measures of  
consistency (eg, I2) for each meta-analysis.
9
Risk of bias  
across trials
15 Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias,  
selective reporting within studies).
9
Additional  
analyses
16 Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-regression), if done,  
indicating which were pre-specified.
9
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for  
exclusions at each stage, ideally with a flow diagram.
10
Study  
characteristics
18 For each study, present characteristics for which data were extracted (eg, study size, PiCOS, follow-up  
period) and provide the citations.
11
Risk of bias  
within studies
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 11
Results of  
individual trials
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for  
each intervention group, (b) effect estimates and confidence intervals, ideally with a forest plot.
11
Synthesis of  
results
21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. 12
Risk of bias  
across studies
22 Present results of any assessment of risk of bias across studies (see item 15). 14
Additional  
analysis
23 Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-regression  
[see item 16]).
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Figure S1 (Continued)
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DISCUSSION
Summary of  
evidence
24 Summarize the main findings including the strength of evidence for each main outcome; consider their  
relevance to key groups (eg, health care providers, users, and policy makers).
14
Limitations 25 Discuss limitations at study and outcome level (eg, risk of bias), and at review-level (eg, incomplete  
retrieval of identified research, reporting bias).
16
Conclusion 26 Provide a general interpretation of the results in the context of other evidence, and implications for  
future research.
16
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (eg, supply of data); role of  
funders for the systematic review.
2
Figure S1 PRiSMA checklist.
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